## **NEW DRUG REVIEW**

Proprietary Name: Enjuvia<sup>TM</sup>

**Common Name: Synthetic Conjugated Estrogens** 

**PDL Category: Estrogens - Tablets** 

	Preferred Drug List/	
Comparable Products	Recommended Drug List Status	
Cenestin®	Preferred	
Premarin®	Preferred	

## **Summary**

Indications and Usage: Treatment of moderate to severe vasomotor symptoms associated with

menopause

Dosage Forms: Tablets; 0.3mg, 0.45mg, 0.625mg, and 1.25mg

**Recommended Dosage:** Start at 0.3mg once daily and adjust dose based on individual response. When used in postmenopausal women with an intact uterus, a progestin should also be initiated.

**Common Adverse Drug Reactions:** Headache, abdominal pain, breast pain

**Contraindications:** Undiagnosed abnormal genital bleeding, history of breast cancer, history of estrogen-dependent neoplasia, history of or active DVT or pulmonary embolism, active or recent arterial thromboembolic disease, hepatic dysfunction, hypersensitivity to any ingredients of the compound, known or suspected pregnancy.

Manufacturer: Duramed Pharmaceuticals, Inc.

**Analysis:** Enjuvia<sup>TM</sup> is a plant-derived formulation of ten synthetic estrogenic substances. The active ingredients are released over several hours due to a unique delivery system called Surelease® which delivers estrogen slowly at a controlled rate. There are no studies to date that compare Enjuvia<sup>TM</sup> to Premarin® or Cenestin®. Other synthetic conjugated estrogen products, both of animal and plant derivation, have preferred status on the PDL that are more cost effective.

delivation, have presented states on the 1 BB that are more cost effective.		
<b>IME Recommendation:</b>	Preferred Drug	Recommended Drug
	Non-Preferred Drug	Non-Recommended Drug
	Preferred Drug with Conditions	